Potential limitations in using minor histocompatibility antigen-specitic cytotoxic T cells for targeting solid tumor cells

被引:13
作者
Miyazaki, M
Akatsuka, Y
Nishida, T
Fujii, N
Hiraki, A
Ikeda, K
Tsujimura, K
Kuzushima, K
Morishima, Y
Sato, S
Ueda, R
Takahashi, T
机构
[1] Aichi Canc Ctr, Res Inst, Div Immunol, Chikusa Ku, Nagoya, Aichi 4648681, Japan
[2] Nagoya City Univ, Sch Med, Dept Internal Med & Mol Sci, Nagoya, Aichi 467, Japan
[3] Nagoya Univ, Grad Sch Med, Dept Mol Med & Clin Sci, Nagoya, Aichi, Japan
[4] Okayama Univ, Sch Med, Dept Internal Med 2, Okayama 700, Japan
[5] Aichi Canc Ctr Hosp, Dept Hematol & Chemotherapy, Nagoya, Aichi 464, Japan
关键词
minor histocompatibility antigen; HA-1; solid tumor; cytotoxic T lymphocyte; transporter associated with antigen processing;
D O I
10.1016/S1521-6616(03)00065-2
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We have shown previously that KIAA0223, a gene encoding a minor histocompatibility antigen, HA-1, whose expression was believed to be restricted to the hematopoietic cells, is aberrantly expressed in some solid tumor cell lines. However, its significance in tumor immunity needs to be determined. Cytotoxic activity of HA-1(H)-specific cytotoxic T lymphocytes (CTLs) was assessed against solid tumor cell lines expressing KIAA0223 using Cr-51 release assays. Five of seven cell lines were lysed when HLA-A*0201 was adequately expressed. One of the two CTL-resistant cell lines became susceptible after treatment with IFN-gamma and TNF-alpha, while the other was lysed only after pulsing with HA-1(H) peptide. In most cell lines tested, HA-1(H) peptide was properly generated and presented for recognition by the CTL. However, impaired antigen processing and presentation observed in this study may result in escape from CTL recognition in vivo, as well as in vitro, as observed in this study. (C) 2003 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:198 / 201
页数:4
相关论文
共 11 条
[1]   Efficient cloning and expression of HLA class I cDNA in human B-lymphoblastoid cell lines [J].
Akatsuka, Y ;
Goldberg, TA ;
Kondo, E ;
Martin, EG ;
Obata, Y ;
Morishima, Y ;
Takahashi, T ;
Hansen, JA .
TISSUE ANTIGENS, 2002, 59 (06) :502-511
[2]   Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: Evidence for a graft-versus-tumor effect [J].
Childs, RW ;
Clave, E ;
Tisdale, J ;
Plante, M ;
Hensel, N ;
Barrett, J .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2044-2049
[3]   The minor histocompatibility antigen HA-1: A diallelic gene with a single amino acid polymorphism [J].
den Haan, JMM ;
Meadows, LM ;
Wang, W ;
Pool, J ;
Blokland, E ;
Bishop, TL ;
Reinhardus, C ;
Shabanowitz, J ;
Offringa, R ;
Hunt, DF ;
Engelhard, VH ;
Goulmy, E .
SCIENCE, 1998, 279 (5353) :1054-1057
[4]   Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer [J].
Eibl, B ;
Schwaighofer, H ;
Nachbaur, D ;
Marth, C ;
Gachter, A ;
Knapp, R ;
Bock, G ;
Gassner, C ;
Schiller, L ;
Petersen, F ;
Niederwieser, D .
BLOOD, 1996, 88 (04) :1501-1508
[5]   CYTOKINE DYSREGULATION AS A MECHANISM OF GRAFT-VERSUS-HOST DISEASE [J].
FERRARA, JLM .
CURRENT OPINION IN IMMUNOLOGY, 1993, 5 (05) :794-799
[6]   Expression of minor histocompatibility antigen, HA-1, in solid tumor cells [J].
Fujii, N ;
Hiraki, A ;
Ikeda, K ;
Ohmura, Y ;
Nozaki, I ;
Shinagawa, K ;
Ishimaru, F ;
Kiura, K ;
Shimizu, N ;
Tanimoto, M ;
Harada, M .
TRANSPLANTATION, 2002, 73 (07) :1137-1141
[7]   Human minor histocompatibility antigens [J].
Goulmy, E .
CURRENT OPINION IN IMMUNOLOGY, 1996, 8 (01) :75-81
[8]   The hematopoietic system-specific minor histocompatibility antigen HA-1 shows aberrant expression in epithelial cancer cells [J].
Klein, CA ;
Wilke, M ;
Pool, J ;
Vermeulen, C ;
Blokland, E ;
Burghart, E ;
Krostina, S ;
Wendler, N ;
Passlick, B ;
Riethmüeller, G ;
Goulmy, E .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (03) :359-368
[9]   Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells [J].
Kondo, E ;
Topp, MS ;
Kiem, HP ;
Obata, Y ;
Morishima, Y ;
Kuzushima, K ;
Tanimoto, M ;
Harada, M ;
Takahashi, T ;
Akatsuka, Y .
JOURNAL OF IMMUNOLOGY, 2002, 169 (04) :2164-2171
[10]   SELECTIVE CHANGES IN EXPRESSION OF HLA CLASS-I POLYMORPHIC DETERMINANTS IN HUMAN SOLID TUMORS [J].
NATALI, PG ;
NICOTRA, MR ;
BIGOTTI, A ;
VENTURO, I ;
MARCENARO, L ;
GIACOMINI, P ;
RUSSO, C .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (17) :6719-6723